Autoantibodies against the water channel AQP4, expressed predominately in central nervous system astrocytes, are markers and pathogenic factors in Devic's disease. In this study we examined whether Multiple Sclerosis (MS) patients recognize antigenic epitopes on AQP4 that may define distinct disease subsets. We screened sera from 45 patients with relapsing-remitting MS (RRMS) and 13 patients with primary progressive MS (PMS). 23 Neuromyelitis Optica (NMO) patients previously characterized were used as assay positive/negative controls. Sera from 23 patients with Systemic Lupus Erythematosus, 23 with primary Sjogren syndrome without neurological involvement and from 28 healthy individuals were also used as controls. NMO-positive sera exhibited reactivity against the intracellular epitope AQPaa252-275, confirming previous observations. All RRMS sera tested negative for anti-AQP4 antibodies using a cell-based assay, but surprisingly, 13% of them reacted with the epitope AQPaa252-275. PMS, healthy and disease controls showed no specific reactivity. Whether these antibodies define distinct MS subsets and have a pathogenic potential pointing to convergent pathogenetic mechanism with NMO, or are simply markers of astrocytic damage, remains to be determined.
Introduction
Multiple sclerosis (MS) is a chronic debilitating autoimmune disease of the central nervous system. It is considered a T-cell orchestrated disorder, although significant evidence supports the notion that B-cell autoimmunity is an important contributor. Histopathological studies have shown the existence of B-cell mediated type II MS (Lucchinetti et al., 2000) and serological studies have described a number of autoantibodies, the most typical being the antibodies against MOG and the most recent being the antibodies against ion channel Kir4.1 (Srivastava et al., 2012) . In contrast, in Neuromyelitis optica (NMO) or Devic's disease the main pathogenetic factor is the antibodies against AQP4, a water channel mainly expressed in astrocytes (Lennon et al., 2005) . On the basis of distinct pathogenetic mechanisms, MS and NMO are considered different disease entities, despite certain radiological and clinical similarities as well as some recent overlapping data that cloud the disease boundaries (Bruck et al., 2012; Siritho et al., 2011) . The suggestion that there may be clinical intermediate types within the spectrum of NMO and MS subsets, prompted us to investigate whether we could detect signs of NMO autoimmunity in typical MS patients. A sensitive ELISA method, recently developed by our group (Kampylafka et al., 2011) to describe the dominant B-cell linear epitopes in NMO-AQP4 positive patients, was employed.
Methods

Patients and sera
Sera was tested from 45 patients with relapsing-remitting MS (RRMS) and 13 patients with primary progressive MS (PMS) diagnosed according to McDonald criteria. 23 patients positive for anti-AQP4 antibodies were selected using a commercially available cell based assay (Euroimmun, Luebeck, Germany). Sera from 28 healthy subjects were used as normal controls. The disease control group comprised of 23 patients with Systemic Lupus Erythematosus (SLE) fulfilling the 1997 American College of Rheumatology revised criteria for the classification of SLE (Hochberg, 1997) and 23 patients with primary Sjögren's Syndrome, without neurological involvement fulfilling the AmericanEuropean Consensus Group revised criteria (Vitali et al., 2002) .
